Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

Blood

Volumn 95, Issue 12, 2000, Pages 3900-3908

  Golay, Josée ^b   Zaffaroni, Luisella ^b   Vaccari, Thomas ^b   Lazzari, Manuela ^b   Borleri, Gian Maria ^b   Bernasconi, Sergio ^b   Tedesco, Francesco ^b   Rambaldi, Alessandro ^b   Introna, Martino ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CYTOLYSIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034660092     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.12.3900.012k14_3900_3908     Document Type: Article

References (42)

1. Reff ME, Carner C, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83: 435-445.
2. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B cell lymphoma. Blood. 1994;84:2457-2466.
3. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
4. Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology. 1998;12:63-76.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
6. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
7. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548-551.
8. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
9. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Annu Rev Immunol. 1998; 9:995-1001.
10. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450-454.
11. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997;25: 705-708.
12. Clark EA, Shu G. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors. J Immunol. 1987;138:720-725.
13. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol. 1985;135:3795-3801.
14. Smiers FJ, van Paassen M, Hählen K, Loewenberg B, Touw IP. CD20 and CD40 mediated mitogenic responses in B lineage acute lymphoblastic leukemias. Br J Haematol. 1996;93:125-130.
15. Golay JT, Crawford DH. Pathways of human B-lymphocyte activation blocked by B-cell specific monoclonal antibodies, Immunol. 1987;62:279-284.
16. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF. The B cell surface molecule B1 is functioanally linked with B cell activation and differentiation. J Immunol. 1985;135:973-979.
17. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. Eur J Immunol. 1986;16:881-887.
18. Holder M, Grafton G, MacDonald I, Finney M, Gordon J. Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur J Immunol. 1995;25:3160-3164.
19. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDC-C2B8) monoclonal antibody sensitises a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177-186.
20. Maloney DG, Smith B, Appelbaum FR. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines (abstract). Blood. 1996;88:637.
21. Bubien JK, Zhou L-J, Bell PD, Frizzel RA, Tedder TF. Transfection of the CD20 cell surface antigen surface molecule into ectopic cell types generates a Ca+ + conductance found constitutively in Blymphocytes. J Cell Biol. 1993;121:1121-1132.
22. Tedder TF, Schlossman SF. Phosphorylation of the B1 (CD20) molecule by normal and malignant human B lymphocytes. J Biol Chem. 1988;263: 10,009-10,015.
23. Genot EM, Meier KE, Licciardi KA, et al. Phosphorylation of CD20 in cells from a hairy cell leukemia cell line. J Immunol. 1993;151:71-82.
24. Popoff IJ, Savage JA, Blake J, Johnson P, Deans JP. The association between CD20 and Src-family tyrosine kinases requires an additional factor. Mol Immunol. 1998;35:207-214.
25. White MW, McDonell F, Shu GL, Morris DR, Clark EA. Activation of dense human tonsillar B cells: induction of c-myc gene expression via two distinct signal transduction pathways. J Immunol. 1991;146:846-853.
26. Golay J, Cusmano G, Introna M. Independent regulation of c-myc, B-myb, and c-myb gene expression by inducers and inhibitors of proliferation in human B lymphocytes. J Immunol. 1992;149: 300-308.
27. Golay J, Capucci A, Arsura M, Castellano M, Rizzo V, Introna M. Expression of c-myb and B-myb, but not A-myb, correlates with proliferation in human hematopoietic cells. Blood. 1991;77: 149-158.
28. Pezzutto A, Doerken B, Moldenhauer G, Clark EA. Amplification of human B cell activation by a monoclonal antibody to the B cell specific antigen CD22. J Immunol. 1987;138:98-106.
29. Lehto T, Meri S. Interaction of soluble CD59 with the terminal complement complexes: CD59 and C9 compete for a nascent epitope on C8. J Immunol. 1993;151:4941-4149.
30. Davies A, Simmons DL, Hale G, et al. CD59, a ly-6 like protein expressed in human lymphoid cells regulates the action of complement membrane attack complex on homologous cells. J Exp Med. 1989;170:637-654.
31. Songia S, Mortellaro A, Tavema S, et al. Characterization of the new immunosuppressive drug undecylprodigiosin in human lymphocytes: retinoblastoma protein, cyclin-dependent kinase-2, and cyclin-dependent kinase-4 as molecular targets. J Immunol. 1997;158:3987-3995.
32. Gorman AM, Hirt UA, Zhivotovsky B, Orrenius S, Ceccatelli S. Application of a fluorometric assay to detect caspase activity in thymus tissue undergoing apoptosis in vivo. J Immunol Methods. 1999;226:43-48.
33. Liszewski M, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol. 1996;61:201-279.
34. Kuraya M, Yefenof E, Klein G, Klein E. Expression of the complement regulatory proteins CD21, CD55, CD59 on Burkitt's lymphoma lines: their role in sensitivity to human serum-mediated lysis. Eur J Immunol. 1992;22:1871-1876.
35. Schmitz J, Zimmer JP, Kluxen B, et al. Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest. 1995; 96:1520-1526.
36. Brasoveanu LI, Altomonte M, Glochini A, et al. Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. Int J Cancer. 1995; 61:548-556.
37. Gorter A, Blok VT, Haasnoot WH, Ensink NG, Daha MR, Fleuren GJ. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role In preventing complement-mediated tumor cell lysis. Lab Invest. 1996;74:1039-1049.
38. Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107, and p130 in the negative control of cell growth. Oncogene. 1998;17:3365-3383.
39. Blok VT, Daha MR, Tijsma O, et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen 3250 enhances C3 deposition and tumor cell lysis by complement. J Immunol. 1998;180:3437-3443.
40. Harris CL, Morgan BP. Characterization of a glycosyl-phosphatidylinositol anchor-deficient subline of Raji cells: an analysis of the functional importance of complement inhibitors on the Raji cell line. Immunology. 1995;86:311-318.
41. Telen MJ, Green AM. The inab phenotype: characterization of the membrane protein and complement regulatory defect. Blood. 1989;74: 437-441.
42. Zaltzman AB, van den Berg CW, Muzykantov VR, Morgan BP. Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulator CD59 and decay accelerating factor. Biochem J. 1995;307:651-656.